Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announced today that Executive Directors of the company will present at several reputed international conferences in November.
Oryzon’s executives will hold business meetings with other companies in the pharmaceutical sector at the 25th Annual International Partnering Conference BIO-Europe 2019 to be held at the Hamburg Messe, Hamburg, Germany, on November 11-13, 2019. Oryzon will discuss the progress in its multipleongoing iadademstat and vafidemstat Phase IIa clinical trial sin oncology and CNS, respectively, with other companies leaders in these indications. Furthermore Dr. Buesa, Oryzon’s CEO,will present the CNS program, vafidemstat,on Monday, November 11, at 15:45 CET at Room 6, Hall B1, Level 1, during the CNS/Neurology track. BIO-Europe is an annual event specialized in partnering and licensing alliances in the pharmaceutical sector. For more info about this event, please visit https://ebdgroup.knect365.com/bioeurope/
In addition,Oryzon’s executives will participate in the by-invitation only Healthcare Conference organized by Jefferies Investment Bank,which will be held in London, UK, on November 20-21, 2019. Furthermore, Dr. Buesa will give a corporate presentation on Thursday, November 21, at 14:20 local time. For more information about this conference, please visit https://www.jefferies.com/IdeasAndPerspectives/Conferences/325/112019
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The results show that adenocarcinoma exhibits much more active and fun...
